9027: A Protocol Pre-specified Interim Overall Survival (OS) Analysis of GEMSTONE-302: A Phase 3 Study of Sugemalimab versus Placebo plus Platinum-based Chemotherapy (Chemo) as First-line (1L) Treatment for Patients with Metastatic Non-small Cell Lung Cancer

Caicun Zhou¹, Ziping Wang², Meili Sun³, Lejie Cao⁴, Zhiyong Ma⁵, Rong Wu⁶, Yan Yu⁷, Wenxiu Yao⁸, Si Sun⁹, Jianhua Chen¹³, You Lu¹⁴, Chunhong Hu¹⁵, Jingru Wang¹⁶, Rumei Chen¹⁶, Mengmeng Qin¹⁶, Hao Wang¹⁶, Jason Yang¹⁶ 1. Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; 2. Peking University Cancer Hospital, Hefei, China; 5. The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 6. Shengjing Hospital of China Medical University, HuaXiang Branch Hospital, Shenyang, China; 7. Harbin Medical University Shanghai Cancer Center, Shanghai, China; 10. Hunan Cancer Hospital, Changsha, China; 11. Fujian Provincial Cancer Hospital, Fuzhou, China; 12. The First Hospital of Jilin University, Changchun, China; 13. The Affiliated Hangzhou, China; 14. West China Hospital, Sichuan University, Changchun, China; 15. The Second Xiangya Hospital of Central South University, Hunan, China; 16. CStone Pharmaceuticals (Su Zhou) Co., Ltd., Suzhou, China

BACKGROUND

- Sugemalimab is a full length, fully human anti-PD-L1 (programmed death ligand-1) immunoglobulin G4 (IgG4, s228p) monoclonal antibody
- GEMSTONE-302, a randomised, double-blind, phase 3 study, previously met its primary endpoint and demonstrated statistically significant and clinically meaningful prolongation of investigator-assessed progression-free survival (PFS) with sugemalimab + chemo vs placebo + chemo as a first-line treatment in patients with metastatic NSCLC
- PFS benefit was observed in both squamous (sq) and non-squamous (nsq) NSCLC, regardless of PD-L1 expression levels¹
- Sugemalimab in combination with chemotherapy has been approved in China for the firstline treatment of patients with metastatic NSCLC²
- Here we report the data from a protocol pre-specified interim OS analysis

M E T H O D S


Study Design

Patients with systemic treatment-naive stage IV NSCLC, measurable disease per RECIST v1.1, ECOG PS 0-1, and no known EGFR, ALK, ROS1 and RET alterations were randomised 2:1 to receive sugemalimab (1200 mg, IV) or placebo plus chemo (sq-NSCLC: carboplatin + paclitaxel; nsq-NSCLC: carboplatin + pemetrexed) every 3 weeks for up to 4 cycles, followed by maintenance therapy (sq-NSCLC: sugemalimab/placebo; nsq-NSCLC: sugemalimab/placebo + pemetrexed). Patients in placebo group could cross over to receive sugemalimab monotherapy upon disease progression.

Endpoints

- Primary endpoint was investigator-assessed PFS
- Key secondary endpoints included OS, investigator-assessed PFS in patients with tumor PD-L1 expression ≥1%, and investigator-assessed ORR

Figure 1. Study Design and Statistical Considerations of GEMSTONE-302



RESULTS

Baseline Characteristics and Patient Disposition

- As of 22 Nov 2021, among all 479 enrolled patients, 51 (15.9%) and 7 (4.4%), respectively, remained on treatment with sugemalimab + chemo or placebo + chemo
- 174 (54.4%) patients in sugemalimab + chemo group and 113 (71.1%) patients in placebo + chemo group discontinued from study, most discontinuations were due to death
- The median follow-up was 25.4 and 24.9 months, respectively
- 49.1% and 65.4% of the patients received ≥ 1 subsequent anti-cancer therapy, respectively. Among which, 17.8% and 43.4% of the patients, respectively, received anti-PD-(L)1-containing therapies, including 45 (28.3%) patients in the placebo+chemo group received on-study crossover sugemalimab treatment post disease progression (**Tab 2**)

Reference: 1. Dhillon S, Duggan S. Drugs. 2022;10.1007/s40265-022-01693-4. 2. Zhou C, Wang Z, Sun Y, et al. Lancet Oncol. 2022;23(2):220-233.

Table 1. Baseline Characteristics

Age, Median (range), Years
Sex, Male, n (%)
ECOG performance status, n (%)
0
1
Tumour pathological type, n (%)
Squamous Cell Carcinoma
Non-squamous Cell Carcinoma
Tumour PD-L1 expression, n (%)
<1%
≥1%
Smoking status, n (%)
Never
Current or former
Baseline liver metastasis, Yes, n (%
Baseline brain metastasis, Yes, n (%

Table 2. Subsequent Anti-cancer Therapy

Number (%) of patients with ≥1 sub

Anti-PD-(L)1-containing therapies

- Non-study PD-(L)1
- On study cross-over sugemalim Others

[#] Subsequent anti-cancer therapies are not mutually exclusive, patients may have received more than one therapies


*The patients may have received both non-study PD-(L)1 and on study cross-over sugemalimab

Efficacy

Overall Survival

- (Fig 2A)
- OS 19.4 vs. 14.8 months, HR = 0.66) (Fig 2B)

population



Sugemalimab + Chemo	Placebo + Chemo
N = 320	N = 159
62.0 (29 - 75)	64.0 (36 - 75)
254 (79.4%)	129 (81.1%)
59 (18.4%)	25 (15.7%)
261 (81.6%)	134 (84.3%)
129 (40.3%)	63 (39.6%)
191 (59.7%)	96 (60.4%)
124 (38.8%)	64 (40.3%)
196 (61.3%)	95 (59.7%)
88 (27.5%)	40 (25.2%)
232 (72.5%)	119 (74.8%)
39 (12.2%)	18 (11.3%)
50 (15.6%)	17 (10.7%)

	Sugemalimab + Chemo	Placebo + Chemo
	N = 320	N = 159
sequent therapies [#]	157 (49.1%)	104 (65.4%)
s*	57 (17.8%)	69 (43.4%)
	41 (12.8%)	29 (18.2%)
nab	18 (5.6%)	45 (28.3%)
	148 (46.3%)	85 (53.5%)

Median OS was 25.4 months in sugemalimab + chemo group vs. 16.9 months in placebo + chemo group (HR=0.65 [95%CI, 0.50-0.84], p=0.0008), and 2-year OS rate was 51.7% vs. 35.6%

OS benefits were observed across all subgroups including different tumor pathology (sq: median OS 23.3 vs. 12.2 months, HR = 0.56; nsq: median OS 26.9 vs. 19.8 months, HR = 0.72) and PD-L1 expression levels (≥1%: median OS 27.0 vs. 19.0 months, HR = 0.64; <1%: median

Figure 2. Overall Survival (A) Kaplan–Meier estimates of overall survival in the intent-to-treat (ITT)


3	Number of events/ number of patients (%)		Median overall survival, months (95% Cl)		
		Placebo group (n=159)	Sugemalimab group (n=320)	Placebo group (n=159)	
Age, years					
<65	98/202	55/91	25.4	16.7	F
≥65	58/118	42/68	23.6	16.9	F
Sex					
Male	133/254	82/129	22.8	15.4	
Female	23/66	15/30	—	23.5	
Smoking status	/	/			
Never	38/88	24/40		16.9	
Current or former smoker	⁻ 118/232	73/119	24.2	16.7	
ECOG PS	24/50	10/05		22.6	
0	21/59	12/25		23.6	-
1 Tumour nothelesical turn	135/261	85/134	23.3	15.4	
Tumour pathological type Non-squamous	86/191	54/96	26.9	19.8	
Squamous	70/129	43/63	23.3	12.2	⊢
Tumour PD-L1 expression		45/05	23.5	12.2	
<1%	70/124	43/64	19.4	14.8	F
≥1%	86/196	54/95	27.0	19.0	F
1-49%	46/92	27/48	23.3	17.7	F
≥50%	40/104	27/47	_	19.8	
Brain metastases	•				
Yes	25/50	14/17	22.1	9.0 ⊢	-
No	131/270	81/140	25.4	17.8	
Liver metastases					
Yes	27/39	12/18	16.6	12.0	H
No	129/281	85/141	27.4	17.8	I
All patients	156/320	97/159	25.4	16.9	

Updated investigator-assessed PFS

In the intent-to-treat population, median PFS was 9.0 months with sugemalimab + chemo vs. 4.9 months with placebo + chemo (HR = 0.49 [0.40-0.61]), and 2-year PFS rate was 20.8% vs. 7.3% (Fig 3A)

In patients with PD-L1 \ge 1%, the median PFS was 10.9 vs. 4.9 months (HR = 0.48 [0.36-0.63], p < 0.0001) (Fig 3B); In patient with PD-L1<1%, the median PFS was 7.4 vs. 4.9 months (HR=0.57 [0.41-0.78], nominal p=0.0005) (**Fig 3C**)


Figure 3. Investigator-assessed PFS (A) ITT population. (B) Patients with PD-L1 \ge 1%. (C) Patients with PD-L1 < 1%.








• ORR was 63.4% vs. 40.3% (p < 0.0001) in sugemalimab + chemo group vs. placebo + chemo group; Median DOR was 9.9 vs. 4.4 months, respectively (Fig 4)



Safety

 Sugemalimab + chemo had a manageable safety profile and no new safety signals were identified after a longer follow-up since last report at 2021 WCLC Congress (Fig 5)

Figure 5. Summary of Treatment-emergent Adverse Events (TEAEs)



CONCLUSION

- Sugemalimab plus chemo demonstrated statistically significant and clinically meaningful PFS, OS and ORR improvement compared with placebo plus chemo, the benefit was irrespective of tumour pathology or PD-L1 expression levels
- Median OS: 25.4 vs. 16.9 months, HR = 0.65, p=0.0008
- ⁻ Median PFS: 9.0 vs. 4.9 months, HR = 0.49, p<0.0001
- ORR: 63.4% vs. 40.3%, p<0.0001
- The combination had a manageable safety profile and no new safety signals were identified
- These data support sugemalimab plus chemo as a 1L treatment for patients with metastatic NSCLC

ACKNOWLEDGEMENTS

ClinicalTrials.gov identifier: NCT03789604

We thank the patients who participated in the study, their families, participating study investigators and clinical sites. This study is sponsored by CStone Pharmaceuticals (Su Zhou) Co., Ltd. Medical writing assistance was provided by Dr. Rumei Chen.

Poster presented at American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022•McCormick Place• Chicago, IL & Online Contact corresponding author: caicunzhoudr@163.com, ClinicalDevelopment@cstonepharma.com

DISCLOSURES

- C. Zhou: Honorarium as a speaker; Amoy Diagnositics, Boehringer Ingelheim, CStone Pharmaceuticals, Eli Lilly China, Hengrui Medicine, Innovent Biologics, Luye Pharma, MSD, Qilu Pharmaceutical, Roche, Sanofi, TopAlliance Biosciences; Advisor: Hengrui Medicine, Innovent Biologics, Qilu Pharmaceutical, TopAlliance Bioscience Z. Wang, M. Sun, L. Cao, Z. Ma, R. Wu, Y. Yu, W. Yao, S. Sun, J. Chen, W. Zhuang, J. Cui, X. Chen, Y. Lu, and C. Hu have
- J. Wang, R. Chen, M. Qin, H. W, J. Yang are employees of CStone Pharmaceuticals (Su Zhou) Co., Lto

Scan to download a reprint of this poste Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors



